10-07-2025
Life Sciences BC Announces 2025 Awards Winners, Honouring Excellence in Health Innovation
Article content
VANCOUVER, British Columbia — Life Sciences BC (LSBC) is pleased to announce the recipients of the 27th Annual Life Sciences BC Awards. These awards honour the exceptional achievements of individuals and organizations across British Columbia's life sciences sector that have successfully advanced health innovations and significantly enriched our dynamic ecosystem.
Article content
Award winners will be recognized in person at the 27th Annual Life Sciences BC Awards Gala on October 2, 2025, at the Vancouver Convention Centre West. This is a memorable evening where the life sciences community's most influential figures gather to celebrate excellence. Learn more and get your tickets before the early bird deadline on July 31, 2025, here. 2025 Life Sciences BC Awards Winners Company & Organizational Awards
Company of the Year: Zymeworks
Emerging Company of the Year – Biotech: Variational AI
Emerging Company of the Year – MedTech: Arbutus Medical
Strategic Partner of the Year: Providence Health Care Ventures
Deal of the Year: NanoVation Therapeutics
Individual Awards
Dr. Don Rix Lifetime Achievement Award: Dr. Michael Hayden
Milton Wong Community Leadership Award: Ali Ardakani
Scientific Entrepreneurship Award: Dr. Poul Sorensen
Genome British Columbia Award for Scientific Excellence: Dr. Fiona Brinkman
Companies to Watch – Recognition Honour Roll*:
Avee Health
CereCura Nanotherapeutics
GuideStar Medical Devices
Optigo Biotherapeutics
Phyton Biotech
* Note: This is not a competitive award category but a recognition of emerging companies demonstrating significant potential within the BC life sciences ecosystem. 'Being named Life Sciences BC's 2025 Company of the Year is a tremendous honour and a reflection of the commitment to scientific innovation and collaboration here at Zymeworks,' said Dr. Paul Moore, Chief Scientific Officer, Zymeworks. 'Over the past year, we have seen the true impact of our world-class R&D engine on patients with limited treatment options, including the FDA approval of zanidatamab as the first HER2-targeted bispecific antibody for HER2-positive biliary tract cancer. This milestone would not have been possible without our team's exemplary scientific expertise, and we are proud that innovation developed here in British Columbia is helping to deliver novel therapies to patients around the world, who inspire our work each day.'
Article content
Article content
'We're proud to recognize individuals and organizations that have dedicated their talents to advancing our sector. I'm extremely excited about this year's award recipients. Advances in therapeutics, AI in drug discovery, medical devices, technology commercialization, and lipid nanoparticles stood out this year. Congratulations to Dr. Michael Hayden, Ali Ardakani, Dr. Poul Sorensen, and Dr. Fiona Brinkman for their incredible leadership within our vibrant life sciences community. ' – Wendy Hurlburt, President & CEO, Life Sciences BC.
Article content
Technology Sponsor
Article content
Farris
Article content
Event Supporter
Article content
Stem Cell Network
Article content
For sponsorship opportunities for the 27th Annual LSBC Awards Gala, please get in touch with Joanne Lin, Manager, Memberships & Sponsorships, at jlin@
Article content
Life Sciences BC (LSBC) is a not-for-profit sector association dedicated to advancing British Columbia's life sciences ecosystem through strategic initiatives at the local, national, and international levels. We drive economic growth in the province by providing leadership, fostering investment and partnerships, collaborating with government, and promoting BC's world-class life sciences sector.
Article content
Article content
Article content
Article content
